specialising in pharmaceutical intermediates and speciality chemicals.Evolution of Business The company is changing its focus from Intermediates for Off-patent and generic drugs towards patented molecules requiring strong technical know how. The revenue contribution from Intermediates has also shifted from 90% to <60%.
Shree Ganesh Remedies Limited has announced its 31st Annual General Meeting (AGM) will be held virtually on September 12 at 11:30 a.m. via Video Conference/Other Audio Visual Means. The company dispatched the Annual Report for FY2025-26 and AGM Notice electronically, also available on its website and CDSL. Shareholders can vote...
Shree Ganesh Remedies Limited's Board has appointed Ms. Hiral Ankitkumar Shah as an Additional Non-Executive Independent Director for a five-year term, subject to shareholder approval. This decision followed a proposal from the Nomination and Remuneration Committee. Ms. Shah is a qualified Company Secretary with over 14 years of experience in...
Shree Ganesh Remedies confirms all its shares are held in dematerialized (electronic) form. The company's share transfer agent reported no requests were received for converting shares back to physical form during the quarter ended June 30, 2026. This streamlined electronic holding ensures efficient share management and liquidity for investors, reflecting...
Shree Ganesh Remedies Limited clarified recent significant share price movement, stating that the fluctuations are purely market-driven. The company's management has no control over or knowledge of specific reasons for this movement. The company reaffirmed its commitment to making all necessary disclosures. This update informs shareholders that the company is...
Shree Ganesh Remedies Limited's management has scheduled a meeting with Moneybee Investment Advisors for June 30 at Ankleshwar. This engagement provides an important opportunity for the company to update institutional investors on its business operations and strategic outlook. Such interactions are key for enhancing transparency and fostering strong investor relations,...
